1. Sun X, Zhang J*, Wang L, Tian Z, Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN, Cancer Letters, 2008Apri, 262:201-213
2. Zhang B, Zhang J*, Tian Z. Comparison in the effects of IL-2, IL-12, IL-15 and IFN on gene regulation of granzymes of human NK cell line NK-92, Int Immunopharmacol, 2008 Jul;8(7):989-96.
3. Jiang W, Zhang J*, Tian Z. Functional characterization of the interleukin-15 gene transduction into human natural killer cell line (NKL), Cytotherapy, 2008;10 (3):265-74.
4.Zhang J, Sun R, Tian Z. Human prolactin promotes human secondary immunoglobulin response in human/SCID mouse chimeras. Clin Vaccine Immunol. 2007Jan;14(1):60-4.
5.Zhang X, Zhang J*, Wei H, Tian Z. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep. 2007Jun, 17(6):1377-82.
6.Feng C, Wang HX, Yao CF, Zhang J*, Tian Z. Diammonium glycyrrhizinate, a component of Traditional Chinese Medicine Gan-Cao, prevents murine T cell-mediated fulminant hepatit is in IL-10- and IL-6-dependent manners. Int Immunopharmacol 2007Oct, 7: 1292–1298;
7.Zhang X, Zhang J*, Wei H, Tian Z.Therapeutic effects of STAT3-decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 2007Aug, 7:149;
8. Liu X, Li J and Zhang J*. STAT3-Decoy ODN Inhibits Cytokine Autocrine of Murine Tumor Cells, Cell Mol Immunol 2007Agu;4(4):309-313;
9. Zhang J, Sun R, Liu J, Wang L, Tian Z. Reverse of NK cytolysis resistance of type II cytokine predominant-human tumor cells. Int Immunopharmacol 2006Jul,6:1176–1180.
10. Wei H, Zhang J, Xiao W, Feng J, Sun R, Tian Z.Involvement of human natural killer cells in asthma pathogenesis: Natural killer 2 cells in type 2 cytokine predominance. J Allergy Clin Immunol, 2005Apr, 115(4): 841-7.
11. Zhang J, Sun R, Wei H, Tian Z.Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft. Int Immunopharmacol, 2005Feb, 5(2): 417-425
12. Zhang J, Sun R, Wei H, Zhang J, Tian Z.Characterization of interleukin-15 gene-modified human natural killer cells for adoptive cellular immunotherapy. Haematologica. 2004Mar, 89(3): 338-347
13.Zhang J, Sun R, Wei H, Zhang J, Tian Z.Characterization of stem cell factor gene-modified human natural killer cell line, NK -92 cells. Oncology Rep. 2004May, 11(5): 1097-1106
14. Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, Tian Z, Zhang J*. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol. 2008 Apr 16; [Epub ahead of print]
15. Su YH, Li G, Zhang XL, Gu JH, Zhang C, Tian ZG, Zhang J*. JSI-124 Inhibits Glioblastoma Multiforme Cell Proliferation through G2/M Cell Cycle Arrest and Apoptosis Augment. Cancer Biology & Therapy. 2008 May 10;7(8). [Epub ahead of print]
* Corresponding author
專利:
1. 國家發(fā)明專利:白細胞介素-15基因修飾的自然殺傷細胞株及其制備方法CN1493687(2/5)
1.重要疾病的免疫基因治療研究(子課題:基因誘騙技術治療疾病的應用基礎研究),科技部973項目(2004CB518807),60萬元,2004.12-2009.1,骨干
2.人類肝臟結構蛋白質組和蛋白質組新技術新方法研究(子課題:抗體對比吸附技術高通量選篩肝臟膜蛋白)科技部973項目(2004CB520804),30萬元,2004.12-2005.01,骨干
3.應用雙核轉錄因子誘騙技術阻斷腫瘤對免疫應答的負調節(jié),30571696,國家自然基金,26萬元,2006.01-2008.12,負責人
4. 人類"調節(jié)性NK細胞(NK-reg)"亞群的發(fā)現及特性研究,30671901,國家自然科學基金,20萬元,2007.1-2009.12, 負責人
5. 感染與免疫的基礎研究(子課題:固有免疫在殺滅和清除病原微生物中的作用和機理), 科技部973項目2006CB504300, 80萬元,2006.12-2011.12, 骨干
6. 核轉錄因子與免疫應答的負調控,國家杰出青年基金海外青年學者合作研究基金,國家自然科學基金,40萬元,2007.1-2009.12,國內合作者
7.重大疾病的基因治療(子課題:腫瘤基因治療產品的臨床前研究),863重點項目,36萬元,2007.6-2009.6
8.基因修飾的治療性NK細胞的建株及臨床前研究,國家863項目(2002AA216151),60萬元,2002.12-2005.12,副組長